Sensorion SAS stock analysis
Sensorion SAS (RFM0) Stock Price & Analysis
RFM0 Stock Chart & Stats
- Day’s Range
- EUR 7.75 - EUR 8.40
- 52-Week Range
- EUR 0.22 - EUR 32.50
- Previous Close
- EUR 8.50
- Volume
- N/A
- Average Volume (3M)
- 6
- Market Cap
- EUR 81.46M
- Enterprise Value
- EUR 28.69M
- Total Cash (Recent Filing)
- EUR 88.49M
- Total Debt (Recent Filing)
- EUR 3.20M
- Price to Earnings (P/E)
- ―
- Beta
- 0.75
- Next Earnings
- Mar 18, 2027 (Est.)
- EPS Estimate
- -2.01
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Focused Inner-ear Pipeline
A focused development strategy in hearing and vestibular disorders gives Sensorion a clear therapeutic identity and targets areas described as having unmet medical needs. If candidates advance successfully, this specialization can support differentiated positioning within otology over the next several quarters.
Low Financial Leverage
Low leverage reduces the burden of mandatory debt servicing and preserves more financial flexibility than a highly indebted structure would provide. This can help the company direct available resources toward research and development while limiting immediate balance-sheet pressure.
Historical Revenue Expansion
Revenue growth through 2024 shows that the company had previously generated increasing commercial or partnered income before the subsequent disruption. The accompanying strong gross profit indicates that realized revenue can provide attractive contribution economics when activity resumes.
Bears Say
Revenue Disruption
The drop to zero revenue represents a major break from the prior growth trajectory and weakens visibility into near-term operating support. Without recurring revenue, development progress is less able to fund the business internally, increasing dependence on financing or future commercial milestones.
Persistent Operating Losses
Large, recurring operating and net losses show that Sensorion remains in heavy investment mode without demonstrated operating leverage. Continued losses can consume capital faster than the business builds earnings capacity, making future financial performance highly dependent on successful development outcomes.
Sustained Cash Burn
Persistent negative operating and free cash flow indicates that current activities do not fund themselves and that the cash runway remains a central business risk. Ongoing burn increases reliance on external funding, which can constrain strategic flexibility and create dilution or financing pressure.
RFM0 FAQ
What was Sensorion SAS’s price range in the past 12 months?
What is Sensorion SAS’s market cap?
When is Sensorion SAS’s upcoming earnings report date?
How were Sensorion SAS’s earnings last quarter?
Is Sensorion SAS overvalued?
Does Sensorion SAS pay dividends?
What is Sensorion SAS’s EPS estimate?
How many shares outstanding does Sensorion SAS have?
What happened to Sensorion SAS’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sensorion SAS?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Sensorion SAS
Sensorion SA is a clinical-stage biopharmaceutical firm based in Montpellier, France, specializing in the development of therapies for inner ear disorders. Their key initiatives include gene therapy programs: OTOF-GT, designed to restore hearing for individuals with Otoferlin deficiency, and USHER-T1-GT, targeting Usher syndrome Type 1. The company also advances SENS-401, a drug candidate for treating sudden sensorineural hearing loss. Sensorion's broader pipeline encompasses numerous experimental treatments aimed at restoring, treating, and preventing various conditions affecting the inner ear. They hold a collaboration agreement with Institut Pasteur concerning gene therapy for both pediatric and adult deafness. Additionally, Sensorion partners with Sonova Holding AG to integrate genetic analysis into the routine diagnosis of progressive adult hearing loss, combining advanced therapeutic approaches with traditional hearing aids. Founded in 2009, Sensorion SA operates primarily in France.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Frédéric Chéreau
- Employees
- 66
- Website
- www.sensorion.com
- Address
- 375, rue du Professeur Joseph Blayac, Montpellier, OC, 34080, FR
Sensorion SAS (RFM0) Earnings & Revenues
RFM0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |





